The direct-acting antiviral glecaprevir/pibrentasvir (Mavyret) was highly effective and well tolerated in adults with acute ...

HCV—can persist in the livers of those infected and even lead to liver disease or failure in extreme cases. It affects tens ...

This article estimates the comprehensive value of direct-acting antivirals for the treatment of hepatitis C virus using a generalized cost-effectiveness analysis. Objectives: To estimate the ...

Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 Study Showed Low ...

Findings showed that in patients treated with glecaprevir/pibrentasvir, the overall SVR12 rate was 96%, with 0 patients experiencing virologic failure. The Food and ...

Hepatitis C is the leading cause of chronic liver disease and liver cancer in the world and affects an estimated 51 million people globally. Though the viral infection is easily diagnosable and ...

Interferon-Free Treatment: No Longer a Dream? Several studies were presented at both Digestive Disease Week (DDW) 2012 in May and at the European Association for the Study of the Liver (EASL) annual ...

Chronic hepatitis C infection has been linked to a higher risk of pancreatic cancer. Learn more about findings from a major ...

Mental health conditions are common among veterans and may play a larger role than previously recognized in raising liver ...

BOSTON, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral ...